Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 15/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 14/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 12/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.70 |
| ▸ | GAK | O14976 | 1/20 | 0.65 |
| ▸ | PRKACG | P22612 | 1/20 | 0.65 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21986445 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2B | |
| SCHEMBL13782096 | 0.95 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2B | |
| SCHEMBL11938440 | 0.94 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2B | |
| SCHEMBL11938429 | 0.92 | PIK3CA (0.85) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2B | |
| SCHEMBL11938435 | 0.91 | PIK3CA (0.84) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2B | |
| SCHEMBL11938431 | 0.91 | PIK3CA (0.84) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2B | |
| SCHEMBL11938450 | 0.91 | PIK3CA (0.84) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2B | |
| SCHEMBL11938436 | 0.91 | PIK3CA (0.83) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2B | |
| SCHEMBL11938465 | 0.91 | PIK3CA (0.83) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2B | |
| SCHEMBL11938433 | 0.88 | PIK3CA (0.78) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374571-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2024-11-14 | — | — | US | disclosed |
| EP-4395769-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023031781-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374571-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | TP53, TEAD2, SERPINB1 | PIK3CA 676/4885PIK3CD 1487/4885PIK3CB 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.